Wen Jifeng, Xu Jun, Sun Qifeng, Xing Chengliang, Yin Wenzhe
Department of Gastroenterology, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
Department of Orthopedic Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
Mol Med Rep. 2016 May;13(5):4481-6. doi: 10.3892/mmr.2016.5075. Epub 2016 Mar 30.
Long non-coding RNAs (lncRNAs) exert regulatory functions on various biological processes in cancer cells, including proliferation, apoptosis and mobility. Prostate cancer-associated transcript 1 (PCAT-1) is a novel lncRNA that promotes cell proliferation in prostate cancer, however, the effect of PCAT‑1 in hepatocellular carcinoma (HCC) remains to be elucidated. The present study hypothesized that PCAT‑1 also exerts an important effect in HCC. The current study investigated PCAT-1 expression levels in HCC tissue samples and HepG2 and Bel‑7402 cell lines using the reverse transcription-quantitative polymerase chain reaction. The results demonstrated that PCAT-1 was upregulated in HCC tissue samples and cell lines compared with adjacent non‑cancerous tissues and the L02 normal liver epithelial cell line. PCAT‑1 suppression using PCAT‑1 small hairpin RNA in HepG2 and Bel‑7402 cells inhibited cell proliferation and migration, and induced apoptosis. Overexpression of PCAT‑1 induced synthetic plasmid vectors was demonstrated to increase cell proliferation and migration, and inhibit apoptosis. Results from the present study suggest that PCAT‑1 exerts an oncogenic effect in HCC and silencing PCAT-1 may be a potential novel therapeutic strategy for HCC.
长链非编码RNA(lncRNAs)对癌细胞的各种生物学过程发挥调节功能,包括增殖、凋亡和迁移。前列腺癌相关转录本1(PCAT-1)是一种新型lncRNA,可促进前列腺癌中的细胞增殖,然而,PCAT-1在肝细胞癌(HCC)中的作用仍有待阐明。本研究假设PCAT-1在HCC中也发挥重要作用。本研究使用逆转录-定量聚合酶链反应检测了HCC组织样本以及HepG2和Bel-7402细胞系中PCAT-1的表达水平。结果表明,与相邻非癌组织和L02正常肝上皮细胞系相比,PCAT-1在HCC组织样本和细胞系中上调。在HepG2和Bel-7402细胞中使用PCAT-1小发夹RNA抑制PCAT-1可抑制细胞增殖和迁移,并诱导凋亡。使用合成质粒载体过表达PCAT-1可增加细胞增殖和迁移,并抑制凋亡。本研究结果表明,PCAT-1在HCC中发挥致癌作用,沉默PCAT-1可能是HCC一种潜在的新型治疗策略。